Hemothorax as Rare Complication from COVID-19 Infection

Z. Muzaffarr
{"title":"Hemothorax as Rare Complication from COVID-19 Infection","authors":"Z. Muzaffarr","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A4094","DOIUrl":null,"url":null,"abstract":"Introduction The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has been linked with many sequelae not typical of other respiratory viruses. One of the unique features of this virus, known as COVID coagulopathy, has been associated with bleeding and/or clotting diathesis in the setting of a prothrombotic state. This has put patients at risk for hemorrhagic complications such as frank disseminated intravascular coagulation, and antiphospholipid syndrome activation. This is a case of hemothorax as a rare complication of COVID-19 infection. Case Presentation This is the case of a 48 year old male with a history of ESRD requiring dialysis, who presented to our facility with shortness of breath. He was recently admitted a month prior to an outside facility for a dialysis catheter infection and was found to be COVID-19 positive. He received IV antibiotics and supplemental oxygen. He was discharged home with plans for IV antibiotics. He presented to our facility with five days of shortness of breath. In the ED he was afebrile, tachypneic and tested negative for COVID-19. Computed Tomography of the chest was significant for a moderate to large right pleural effusion with loculated components. The next day he underwent a thoracentesis and 600 cc of bloody pleural fluid was aspirated. He then underwent a VATS, decortication, pleurodesis a few days later as the effusion failed to resolve. Cytology of the initial thoracentesis was negative for malignant cells and pathology from the VATS was positive for fibrosis, hemorrhage with fibrin deposition and acute and chronic inflammation. Discussion Hemothorax as a complication of COVID -19 has yet to be described in the literature. Altered markers such as D-dimer and fibrinogen were associated with increased coagulation and thrombotic complications respectively. Furthermore, studies have reported intra-alveolar hemorrhages and GI bleeding in post-mortem analysis of COVID patients. This case highlights the uniqueness of this novel virus and the vast array of complications that can result from infection.","PeriodicalId":23169,"journal":{"name":"TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP100. TP100 UNEXPECTED COVID-19 CASE REPORTS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A4094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has been linked with many sequelae not typical of other respiratory viruses. One of the unique features of this virus, known as COVID coagulopathy, has been associated with bleeding and/or clotting diathesis in the setting of a prothrombotic state. This has put patients at risk for hemorrhagic complications such as frank disseminated intravascular coagulation, and antiphospholipid syndrome activation. This is a case of hemothorax as a rare complication of COVID-19 infection. Case Presentation This is the case of a 48 year old male with a history of ESRD requiring dialysis, who presented to our facility with shortness of breath. He was recently admitted a month prior to an outside facility for a dialysis catheter infection and was found to be COVID-19 positive. He received IV antibiotics and supplemental oxygen. He was discharged home with plans for IV antibiotics. He presented to our facility with five days of shortness of breath. In the ED he was afebrile, tachypneic and tested negative for COVID-19. Computed Tomography of the chest was significant for a moderate to large right pleural effusion with loculated components. The next day he underwent a thoracentesis and 600 cc of bloody pleural fluid was aspirated. He then underwent a VATS, decortication, pleurodesis a few days later as the effusion failed to resolve. Cytology of the initial thoracentesis was negative for malignant cells and pathology from the VATS was positive for fibrosis, hemorrhage with fibrin deposition and acute and chronic inflammation. Discussion Hemothorax as a complication of COVID -19 has yet to be described in the literature. Altered markers such as D-dimer and fibrinogen were associated with increased coagulation and thrombotic complications respectively. Furthermore, studies have reported intra-alveolar hemorrhages and GI bleeding in post-mortem analysis of COVID patients. This case highlights the uniqueness of this novel virus and the vast array of complications that can result from infection.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎感染罕见并发症血胸
由严重急性呼吸综合征冠状病毒2引起的新型冠状病毒病2019 (COVID-19)与许多其他呼吸道病毒不典型的后遗症有关。这种病毒的一个独特特征是COVID - 19凝血功能障碍,它与血栓形成前状态下的出血和/或凝血能力有关。这使患者面临出血性并发症的风险,如弥散性血管内凝血和抗磷脂综合征激活。血胸是COVID-19感染的罕见并发症。这是一个48岁的男性,有ESRD病史,需要透析,以呼吸短促就诊。他最近在一个月前因透析导管感染被送往外部设施,并被发现是COVID-19阳性。他接受了静脉注射抗生素和补充氧气。他出院回家时,计划给他静脉注射抗生素。他到我们这里来的时候有五天的呼吸急促。在急诊室里,他发烧、呼吸急促,COVID-19检测呈阴性。胸部计算机断层扫描对于中度至大量的右侧胸腔积液具有定位成分具有重要意义。第二天,他接受了胸腔穿刺,并抽吸了600毫升带血的胸腔积液。几天后,由于积液未能消除,他接受了VATS、脱屑和胸膜切除术。最初胸腔穿刺的细胞学检查为恶性细胞阴性,VATS病理检查为纤维化、纤维蛋白沉积出血和急慢性炎症阳性。血胸作为COVID -19的并发症尚未在文献中描述。改变标记物如d -二聚体和纤维蛋白原分别与凝血和血栓并发症增加有关。此外,研究报告了COVID患者死后分析中的肺泡内出血和胃肠道出血。该病例突出了这种新型病毒的独特性以及感染可能导致的大量并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The global race to vaccinate Covid-19 vaccine production and tariffs on vaccine inputs Indicative list of trade-related bottlenecks and trade-facilitating measures on critical products to combat covid-19 Joint Indicative List of Critical COVID-19 Vaccine Inputs for Consultation Improving trade data for products essential to fight covid-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1